Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 143026, 10 pages
http://dx.doi.org/10.1155/2010/143026
Research Article

Th1 and Th2 Immune Response in Chronic Hepatitis B Patients during a Long-Term Treatment with Adefovir Dipivoxil

1Department of Hepatology, First Hospital, Jilin University, Changchun 130021, China
2Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA

Received 23 April 2010; Revised 12 July 2010; Accepted 7 September 2010

Academic Editor: Dennis Daniel Taub

Copyright © 2010 Yanfang Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 97–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. W. C. Maddrey, “Hepatitis B: an important public health issue,” Journal of Medical Virology, vol. 61, no. 3, pp. 362–366, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. G. V. Papatheodoridis, S. Manolakopoulos, G. Dusheiko, and A. J. Archimandritis, “Therapeutic strategies in the management of patients with chronic hepatitis B virus infection,” The Lancet Infectious Diseases, vol. 8, no. 3, pp. 167–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C.-L. Lai, R.-N. Chien, N. W. Y. Leung et al., “A one-year trial of lamivudine for chronic hepatitis B,” The New England Journal of Medicine, vol. 339, no. 2, pp. 61–68, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Dienstag, E. R. Schiff, T. L. Wright et al., “Lamivudine as initial treatment for chronic hepatitis B in the United States,” The New England Journal of Medicine, vol. 341, no. 17, pp. 1256–1263, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. Y.-F. Liaw, J. J. Y. Sung, W. C. Chow et al., “Lamivudine for patients with chronic hepatitis B and advanced liver disease,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1521–1587, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. F. Lok, C.-L. Lai, N. Leung et al., “Long-term safety of lamivudine treatment in patients with chronic hepatitis B,” Gastroenterology, vol. 125, no. 6, pp. 1714–1722, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Perrillo, E. Schiff, E. Yoshida et al., “Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants,” Hepatology, vol. 32, no. 1, pp. 129–134, 2000. View at Google Scholar · View at Scopus
  9. Y. Benhamou, M. Bochet, V. Thibault et al., “Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study,” The Lancet, vol. 358, no. 9283, pp. 718–723, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Xiong, C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs, “Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro,” Hepatology, vol. 28, no. 6, pp. 1669–1673, 1998. View at Google Scholar · View at Scopus
  11. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B,” The New England Journal of Medicine, vol. 348, no. 9, pp. 800–807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Marcellin, T.-T. Chang, S. G. L. Lim et al., “Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B,” Hepatology, vol. 48, no. 3, pp. 750–758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Leung, C.-Y. Peng, H.-W. Hann et al., “Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir,” Hepatology, vol. 49, no. 1, pp. 72–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B,” The New England Journal of Medicine, vol. 348, no. 9, pp. 800–807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years,” Gastroenterology, vol. 131, no. 6, pp. 1743–1751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Angus, R. Vaughan, S. Xiong et al., “Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase,” Gastroenterology, vol. 125, no. 2, pp. 292–297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Locarnini and W. S. Mason, “Cellular and virological mechanisms of HBV drug resistance,” Journal of Hepatology, vol. 44, no. 2, pp. 422–431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Zeng, Y. Mao, G. Yao et al., “A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B,” Hepatology, vol. 44, no. 1, pp. 108–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Rehermann and M. Nascimbeni, “Immunology of hepatitis B virus and hepatitis C virus infection,” Nature Reviews Immunology, vol. 5, no. 3, pp. 215–229, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Thimme, S. Wieland, C. Steiger et al., “CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection,” Journal of Virology, vol. 77, no. 1, pp. 68–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Boni, P. Fisicaro, C. Valdatta et al., “Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection,” Journal of Virology, vol. 81, no. 8, pp. 4215–4225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Boni, A. Bertoletti, A. Penna et al., “Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B,” Journal of Clinical Investigation, vol. 102, no. 5, pp. 968–975, 1998. View at Google Scholar · View at Scopus
  23. C. Boni, A. Penna, A. Bertoletti et al., “Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B,” Journal of Hepatology, vol. 39, no. 4, pp. 595–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. G. K. K. Lau, H. Cooksley, R. M. Ribeiro et al., “Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B,” Antiviral Therapy, vol. 12, no. 5, pp. 705–718, 2007. View at Google Scholar · View at Scopus
  25. H. Cooksley, S. Chokshi, Y. Maayan et al., “Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 312–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. T. R. Mosmann and S. Sad, “The expanding universe of T-cell subsets: Th1, Th2 and more,” Immunology Today, vol. 17, no. 3, pp. 138–146, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Duramad, C. W. McMahon, A. Hubbard, B. Eskenazi, and N. T. Holland, “Flow cytometric detection of intracellular Th1/Th2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 9, pp. 1452–1458, 2004. View at Google Scholar · View at Scopus
  28. E. Morgan, R. Varro, H. Sepulveda et al., “Cytometric bead array: a multiplexed assay platform with applications in various areas of biology,” Clinical Immunology, vol. 110, no. 3, pp. 252–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Tárnok, J. Hambsch, R. Chen, and R. Varro, “Cytometric bead array to measure six cytokines in twenty-five microliters of serum,” Clinical Chemistry, vol. 49, no. 6, pp. 1000–1002, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. M. R. Brunetto, F. Moriconi, F. Bonino et al., “Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B,” Hepatology, vol. 49, no. 4, pp. 1141–1150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Lindström, J. Odeberg, and J. Albert, “Pyrosequencing for detection of lamivudine-resistant hepatitis B virus,” Journal of Clinical Microbiology, vol. 42, no. 10, pp. 4788–4795, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A.-Z. Zeng, H. Deng, C. Yang et al., “Hepatitis B virus genotype-associated variability in antiviral response to adefovir dipivoxil therapy in Chinese han population,” Tohoku Journal of Experimental Medicine, vol. 216, no. 3, pp. 205–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Chen, M. Sällberg, J. Hughes et al., “Immune tolerance split between hepatitis B virus precore and core proteins,” Journal of Virology, vol. 79, no. 5, pp. 3016–3027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. T. Chen, J.-N. Billaud, M. Sällberg et al., “A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14913–14918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-P. Villeneuve, D. Durantel, S. Durantel et al., “Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient,” Journal of Hepatology, vol. 39, no. 6, pp. 1085–1089, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. Y.-S. Lee, D. J. Suh, Y.-S. Lim et al., “Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy,” Hepatology, vol. 43, no. 6, pp. 1385–1391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Tan, B. Degertekin, S. N. Wong, M. Husain, K. Oberhelman, and A. S. F. Lok, “Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations,” Journal of Hepatology, vol. 48, no. 3, pp. 391–398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. C.-H. Chen, J.-H. Wang, C.-M. Lee et al., “Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil,” Antiviral Therapy, vol. 11, no. 6, pp. 771–778, 2006. View at Google Scholar · View at Scopus
  39. J. J. Y. Sung, J.-Y. Lai, S. Zeuzem et al., “Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B,” Journal of Hepatology, vol. 48, no. 5, pp. 728–735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. J. S. Tuttleman, C. Pourcel, and J. Summers, “Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells,” Cell, vol. 47, no. 3, pp. 451–460, 1986. View at Google Scholar · View at Scopus
  41. C. Seeger and W. S. Mason, “Hepatitis B virus biology,” Microbiology and Molecular Biology Reviews, vol. 64, no. 1, pp. 51–68, 2000. View at Google Scholar · View at Scopus
  42. I. Fourel, J. M. Cullen, J. Saputelli et al., “Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks,” Journal of Virology, vol. 68, no. 12, pp. 8321–8330, 1994. View at Google Scholar · View at Scopus
  43. L. G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari, “Viral clearance without destruction of infected cells during acute HBV infection,” Science, vol. 284, no. 5415, pp. 825–829, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Ataseven, I. H. Bahcecioglu, N. Kuzu et al., “The levels of ghrelin, leptin, TNF-α, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection,” Mediators of Inflammation, vol. 2006, Article ID 78380, 6 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus